{"id":"bpn14770-zatolmilast","safety":{"commonSideEffects":[{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Vomiting"}]},"_chembl":{"chemblId":"CHEMBL4541964","moleculeType":"Small molecule","molecularWeight":"405.80"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"By selectively inhibiting PDE4D, the drug prevents the breakdown of cyclic adenosine monophosphate (cAMP), leading to elevated cAMP levels in neurons and immune cells. This mechanism is thought to improve synaptic plasticity, enhance memory consolidation, and reduce pro-inflammatory cytokine production, making it potentially beneficial for cognitive disorders and neuroinflammatory conditions.","oneSentence":"BPN14770 is a phosphodiesterase 4D (PDE4D) inhibitor that increases intracellular cAMP levels to enhance cognitive function and reduce neuroinflammation.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:41:48.413Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Cognitive impairment associated with schizophrenia"},{"name":"Alzheimer's disease"}]},"trialDetails":[{"nctId":"NCT05163808","phase":"PHASE2, PHASE3","title":"A Randomized Study of BPN14770 in Male Adolescents (Aged 9 to < 18 Years) With Fragile X Syndrome","status":"COMPLETED","sponsor":"Tetra Discovery Partners","startDate":"2022-03-29","conditions":"Fragile X Syndrome","enrollment":163},{"nctId":"NCT06717438","phase":"PHASE2","title":"Study of Zatolmilast (BPN14770) in Participants With PPP2R5D Neurodevelopmental Disorder (Jordan's Syndrome [JS])","status":"ACTIVE_NOT_RECRUITING","sponsor":"Shionogi","startDate":"2025-05-13","conditions":"Jordan's Syndrome, PPP2R5D Neurodevelopmental Disorder","enrollment":30},{"nctId":"NCT05367960","phase":"PHASE3","title":"An Open-Label Extension Study of BPN14770 in Subjects With Fragile X Syndrome","status":"ACTIVE_NOT_RECRUITING","sponsor":"Tetra Discovery Partners","startDate":"2022-11-01","conditions":"Fragile X Syndrome","enrollment":314},{"nctId":"NCT07011992","phase":"PHASE1","title":"A Study to Assess the Effects of BPN14770 on Rosuvastatin","status":"COMPLETED","sponsor":"Shionogi","startDate":"2025-07-18","conditions":"Healthy Participants","enrollment":12},{"nctId":"NCT05358886","phase":"PHASE3","title":"A Study of BPN14770 in Male Adults (Aged 18 to 45) With Fragile X Syndrome","status":"COMPLETED","sponsor":"Tetra Discovery Partners","startDate":"2022-11-01","conditions":"Fragile X Syndrome","enrollment":171}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"BPN14770/ zatolmilast","genericName":"BPN14770/ zatolmilast","companyName":"Tetra Discovery Partners","companyId":"tetra-discovery-partners","modality":"Small molecule","firstApprovalDate":"","aiSummary":"BPN14770 is a phosphodiesterase 4D (PDE4D) inhibitor that increases intracellular cAMP levels to enhance cognitive function and reduce neuroinflammation. Used for Cognitive impairment associated with schizophrenia, Alzheimer's disease.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}